Israel Englander’s Supernus Pharmaceuticals SUPN Stock Holding History

Israel Englander’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-45,000	Closed	-$2.24M	–	6354
2025 Q4	$2.24M	Sell	45,000 -161,900	-78%	-$7.87M	﹤0.01%	3847
2025 Q3	$9.89M	Buy	+206,900	New	+$8.33M	﹤0.01%	2395
2023 Q3	–	Sell	-60,000	Closed	-$1.8M	–	6543
2023 Q2	$1.8M	Buy	60,000 +10,000	+20%	+$350K	﹤0.01%	3572
2023 Q1	$1.81M	Buy	+50,000	New	+$1.92M	﹤0.01%	3543
2021 Q4	–	Sell	-10,000	Closed	-$267K	–	7363
2021 Q3	$267K	Buy	+10,000	New	+$268K	﹤0.01%	5899

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Israel Englander's SUPN Position: Q2 2026 in Review

Israel Englander increased its Supernus Pharmaceuticals (SUPN) stake by 16% in Q2 2026, buying an estimated $25.8M and bringing the position to 3,853,212 shares worth $179M. The position accounts for 0.06% of the portfolio, ranked #280.

Israel Englander first reported a position in SUPN in Q2 2013 and has held it in 48 quarters since. 331 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Israel Englander held 3,853,212 shares of Supernus Pharmaceuticals worth $179M as of Q2 2026.
Israel Englander bought 537,239 Supernus Pharmaceuticals shares in Q2 2026, an estimated $25.8M.
Supernus Pharmaceuticals made up 0.06% of Israel Englander's portfolio in Q2 2026, its #280 holding.
Israel Englander first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
331 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.